Hector Posso1, Leith León-Maldonado2, Betania Allen-Leigh3, Jorge Salmerón4,5, Manuel Quiterio6, Anna R Giuliano7, Staci L Sudenga7, Alan G Nyitray8, B Nelson Torres7, Martha Abrahamsen7, Eduardo Lazcano-Ponce5. 1. Universidad de la Sabana. Chia-Cundinamarca, Colombia. 2. Cátedra Conacyt, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México. 3. Dirección de Salud Reproductiva, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México. 4. Centro de Investigación en Políticas, Población y Salud, Facultad de Medicina, Universidad Nacional Autónoma de México. Ciudad de México, México. 5. Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México. 6. Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social. Cuernavaca, Morelos, México. 7. Center for Infection Research in Cancer, Moffitt Cancer Center and Research Institute.Tampa, Florida. 8. Department of Epidemiology, The University of Texas School of Public Health. Houston, Texas, USA.
Abstract
OBJECTIVE: Describe the natural history of anal HPV among men. MATERIALS AND METHODS: Prospective study among men 18-70 years (n=665), from Cuernavaca, Mexico who completed questionnaires and provided specimens (HPV genotyped) at enrollment and 1+ follow-up visit. HPV prevalence and incidence were estimated. Prevalence ratios were calculated with Poisson regression using robust variance estimation. Person-time for incident HPV infection was estimated using number of events modeled as Poisson variable for total person-months. RESULTS: Anal infection prevalence: any HPV type=15%, high-risk=8.4%, HPV16=1.4%, tetravalent vaccine types (4vHPV)=4.4%, nonavalent vaccine types (9vHPV)=6.3%. Factors associated with prevalence: 50+ lifetime female sex partners (adjusted prevalence ratio, a PR=3.25, 95% CI:1.12- 9.47), 10+ lifetime male sex partners (aPR=3.06, 95%CI:1.4- 6.68), and 1+ recent male anal sex partners (aPR=2.28, 95%CI:1.15-4.5). Anal incidence rate: high-risk HPV=7.8/1000 person-months (95%CI:6.0-10.1), HPV16=1.8/1000 personmonths (95%CI:1.1-2.9),4vHPV=3.4/1000 person-months (95%CI:2.3-4.9) and 9vHPV=5.5/1000 person-months (95%CI:4.1-7.5). CONCLUSIONS: Implementation of universal HPV vaccination programs, including men, is a public health priority.
OBJECTIVE: Describe the natural history of anal HPV among men. MATERIALS AND METHODS: Prospective study among men 18-70 years (n=665), from Cuernavaca, Mexico who completed questionnaires and provided specimens (HPV genotyped) at enrollment and 1+ follow-up visit. HPV prevalence and incidence were estimated. Prevalence ratios were calculated with Poisson regression using robust variance estimation. Person-time for incident HPV infection was estimated using number of events modeled as Poisson variable for total person-months. RESULTS:Anal infection prevalence: any HPV type=15%, high-risk=8.4%, HPV16=1.4%, tetravalent vaccine types (4vHPV)=4.4%, nonavalent vaccine types (9vHPV)=6.3%. Factors associated with prevalence: 50+ lifetime female sex partners (adjusted prevalence ratio, a PR=3.25, 95% CI:1.12- 9.47), 10+ lifetime male sex partners (aPR=3.06, 95%CI:1.4- 6.68), and 1+ recent male anal sex partners (aPR=2.28, 95%CI:1.15-4.5). Anal incidence rate: high-risk HPV=7.8/1000 person-months (95%CI:6.0-10.1), HPV16=1.8/1000 personmonths (95%CI:1.1-2.9),4vHPV=3.4/1000 person-months (95%CI:2.3-4.9) and 9vHPV=5.5/1000 person-months (95%CI:4.1-7.5). CONCLUSIONS: Implementation of universal HPV vaccination programs, including men, is a public health priority.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: Peter V Chin-Hong; Eric Vittinghoff; Ross D Cranston; Susan Buchbinder; Daniel Cohen; Grant Colfax; Maria Da Costa; Teresa Darragh; Eileen Hess; Franklyn Judson; Beryl Koblin; Maria Madison; Joel M Palefsky Journal: J Infect Dis Date: 2004-11-10 Impact factor: 5.226
Authors: E I Svare; S K Kjaer; A M Worm; A Osterlind; C J L M Meijer; A J C van den Brule Journal: Sex Transm Infect Date: 2002-06 Impact factor: 3.519
Authors: Jeffrey M Partridge; James P Hughes; Qinghua Feng; Rachel L Winer; Bethany A Weaver; Long-Fu Xi; Michael E Stern; Shu-Kuang Lee; Sandra F O'Reilly; Stephen E Hawes; Nancy B Kiviat; Laura A Koutsky Journal: J Infect Dis Date: 2007-09-13 Impact factor: 5.226
Authors: Anna R Giuliano; Eduardo Lazcano-Ponce; Luisa L Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary R Papenfuss; Martha Abrahamsen; Emily Jolles; Carrie M Nielson; Maria Luisa Baggio; Roberto Silva; Manuel Quiterio Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Fengyi Jin; Garrett P Prestage; John Imrie; Susan C Kippax; Basil Donovan; David J Templeton; Anthony Cunningham; Adrian Mindel; Philip H Cunningham; John M Kaldor; Andrew E Grulich Journal: J Acquir Immune Defic Syndr Date: 2010-01 Impact factor: 3.731